pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 45 Non-oncology: 29
Oncology: 16
Under Consideration for Negotiation 13 Non-oncology: 9
Oncology: 4
Completed Negotiations 785 With Letter of Intent: 678
Without agreement: 107
Negotiations That Were Not Pursued 108

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Zilbrysq UCB Canada Inc. Generalized myasthenia gravis (gMG)
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia (non-familial and heterozygous familial)
Vyloy Astellas Pharma Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal
Winrevair Merck Canada Inc. Pulmonary Arterial Hypertension (WHO group 1)
Ojjaara GlaxoSmithKline Inc. For the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary myelofibrosis (MF), post polycythemia vera myelofibrosis or post essential thrombocythemia MF who have moderate to severe anemia.
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Balversa Janssen Inc. Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior th
Vabysmo Hoffmann-La Roche Ltd. Retinal vein occlusion

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Trodelvy Gilead Sciences Canada Inc. Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
Tecvayli Janssen Inc. Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre
Cabtreo Bausch Health, Canada Inc. Acne Vulgaris
Xcopri Paladin Labs Inc. Epilepsy, partial-onset seizures
Xtandi Astellas Pharma Inc. ​For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Beqvez Pfizer Canada ULC Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74
Elrexfio Pfizer Canada ULC Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks